Instalab

Proinsulin Test

Spot the earliest signs of insulin-producing cell strain years before your blood sugar ever climbs.

Who benefits from Proinsulin testing

Worried About Diabetes in Your Family
This test reveals beta cell strain that can appear years before blood sugar rises, especially in those with a family history.
Told Your Blood Sugar Is Borderline
See whether your insulin-producing cells are struggling to keep up, even when glucose is only slightly off.
Tracking Hidden Heart Disease Risk
Elevated levels independently predict cardiovascular events, even when standard cholesterol and glucose look normal.
Healthy but Want to Stay Ahead
Get an early baseline on beta cell function so you can spot changes over time and act before problems appear.

About Proinsulin

Your pancreas does not release insulin in its finished form. It first builds a larger molecule called proinsulin, then trims it into two pieces: mature insulin and a fragment called C-peptide. When the insulin-producing cells (called beta cells) are healthy and keeping up with demand, almost all of the proinsulin gets converted before it leaves the cell. But when those cells are overworked, stressed, or beginning to fail, they start releasing unconverted proinsulin into the bloodstream. That spillover is what this test catches.

What makes proinsulin uniquely valuable is timing. Standard blood sugar markers like glucose and HbA1c only budge once your body has lost a significant amount of its ability to regulate blood sugar. Proinsulin can rise years, even decades, before glucose does. In one study following men for 27 years, elevated proinsulin independently predicted who would develop type 2 diabetes, even after accounting for body weight and fasting glucose. That kind of early warning is hard to get from a routine lab panel.

How Proinsulin Processing Works

Proinsulin (the full name for this precursor) is a single chain of about 86 amino acids that contains the blueprint for insulin within it. Inside each beta cell, proinsulin folds into its three-dimensional shape in a compartment called the endoplasmic reticulum (essentially the cell's protein-folding workshop). It then moves through an internal shipping system to storage compartments called secretory granules, where specialized cutting enzymes snip it into mature insulin and C-peptide.

In a healthy beta cell, over 99% of proinsulin gets fully converted before it is released. When the process works well, only a tiny amount of intact proinsulin leaks into the blood. When the process breaks down, whether from chronic overwork, metabolic stress, or intrinsic beta cell damage, that percentage climbs. The ratio of proinsulin to insulin in your blood is essentially a report card on how well your beta cells are handling their workload.

Type 2 Diabetes Risk

Proinsulin's ability to predict type 2 diabetes has been tested in several large, long-running studies. In the Uppsala Longitudinal Study, 874 men were followed from age 50 for 27 years. During that time, a third of them developed type 2 diabetes. Elevated intact proinsulin at baseline independently predicted who would develop the disease, with about 57% higher odds per standard-deviation increase, even after adjusting for body weight, fasting glucose, and early insulin response.

The Insulin Resistance Atherosclerosis Study (IRAS) followed 903 adults without diabetes for five years. Each standard-deviation increase in intact proinsulin was associated with roughly 90% higher odds of developing diabetes. Those odds held up after adjusting for body mass, glucose tolerance, and insulin sensitivity. People with both high proinsulin and a sluggish early insulin response had the steepest risk.

A population study of 9,396 Finnish men confirmed that both fasting and post-glucose proinsulin levels predicted worsening blood sugar control and new diabetes diagnoses over six years. Proinsulin captures something distinct from simple insulin resistance: it reflects a processing defect inside the beta cell itself.

Heart Disease and Mortality

Proinsulin does not just predict diabetes. It independently predicts cardiovascular events and death, even in people whose blood sugar looks fine. A meta-analysis reviewing 19 Western prospective studies of insulin-related markers (three of which specifically measured proinsulin) found that people in the top third of proinsulin levels were about 2.2 times as likely to develop coronary heart disease compared to those in the bottom third.

Who Was StudiedWhat Was ComparedWhat They Found
874 men followed from age 50 for 27 yearsProinsulin level and coronary heart disease deathAbout 47% higher risk per standard-deviation increase, even after adjusting for smoking, blood pressure, cholesterol, BMI, and glucose
604 adults in the Hoorn Study, followed 11 yearsFasting proinsulin and all-cause and cardiovascular deathAbout 21% higher risk of all-cause death and 33% higher risk of cardiovascular death per interquartile range increase (the spread between the 25th and 75th percentile)
1,181 non-diabetic men aged 50 to 64, followed 10 to 14 yearsProinsulin-like molecules and coronary heart diseaseAbout 54% higher odds per standard-deviation increase in total proinsulin-like molecules, adjusted for age and BMI

Sources: Zethelius et al., Circulation 2002; Alssema et al., Diabetes Care 2005; Yudkin et al., Diabetologia 2002.

What makes these findings striking is that standard insulin measurements did not show the same predictive power. In the Uppsala study, specific insulin was not a significant predictor of coronary death. Proinsulin captured a risk dimension that insulin alone missed.

Stroke Risk

The cardiovascular signal extends to stroke. In a study of 1,151 elderly men followed for nearly nine years, each standard-deviation increase in fasting proinsulin was linked to about 22% higher risk of stroke or transient ischemic attack (a brief episode where blood flow to the brain is temporarily blocked), even after adjustment for diabetes, high blood pressure, and other established risk factors. A separate case-control study in northern Sweden found that high proinsulin preceded first-ever stroke with roughly 3.4 times the odds compared to low levels. Women in that study showed an especially large signal.

Insulin Resistance and Metabolic Syndrome

A disproportionately high proinsulin-to-insulin ratio is a hallmark of the cluster of metabolic problems that often travel together: high blood pressure, elevated triglycerides, low HDL cholesterol, and impaired glucose tolerance. The ratio increases as more of these features accumulate. A fasting intact proinsulin above 10 pmol/L (a unit for very small concentrations in blood) was very accurate at ruling in insulin resistance when present (93 to 100% specificity) in people with type 2 diabetes, though it only caught about half of cases (47 to 49% sensitivity).

A common misconception is that elevated proinsulin simply reflects the increased secretory demand of obesity. Research contradicts this. Obese individuals without diabetes actually had lower proinsulin-to-insulin ratios than lean individuals, showing that their beta cells were keeping up with the extra demand. Disproportionate hyperproinsulinemia signals a processing defect inside the beta cell, not just overwork.

Early Beta Cell Dysfunction in At-Risk Families

If you have a parent or sibling with type 2 diabetes, your beta cells may already be showing subtle strain even if your glucose is perfectly normal. A study of nondiabetic offspring of diabetic parents found that proinsulin levels and the proinsulin-to-insulin ratio were disproportionately elevated compared to controls, pointing to early processing problems that standard glucose testing would not detect. Separate research showed that this elevation can appear at glucose levels still well within the normal range, around 96 to 98 mg/dL.

Reference Ranges

Proinsulin assays are not standardized across laboratories, so the exact numbers on your report will depend on which test your lab uses. Always compare results within the same lab over time rather than against a universal threshold. That said, published research provides useful orientation.

TierFasting Range (pmol/L)What It Suggests
FavorableBelow approximately 7 pmol/LBeta cells are processing proinsulin efficiently; lower cardiovascular and diabetes risk in population studies
IntermediateApproximately 7 to 10 pmol/LBeta cell function appears adequate, but tracking the trend over time is worthwhile, especially with metabolic risk factors
ElevatedAbove approximately 10 pmol/LHigh specificity for insulin resistance; associated with increased cardiovascular and diabetes risk in multiple prospective studies
Strongly elevated (post-meal)Above 15 pmol/L postprandiallyIn point-of-care testing, this threshold showed 85% sensitivity and 100% specificity for identifying beta cell dysfunction and predicting type 2 diabetes within 5 to 7 years

These tiers are drawn from published research. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. A validated ELISA assay in healthy, non-obese adults established a fasting reference range of 2.7 to 14.2 pmol/L during a standard glucose tolerance test.

Why One Reading Is Not Enough

Proinsulin has high biological variability. Data from the Hoorn Study showed that the test-to-test variation for fasting proinsulin is approximately 100% of the median value, meaning that in someone with a typical level of 8 pmol/L, a second fasting draw could plausibly come back anywhere from near zero to 16 pmol/L. This variation comes primarily from genuine biological fluctuations rather than lab error. Modern assays have analytical precision well under 10%, so the measurement itself is reliable; it is your body's output that varies from day to day.

This makes serial tracking essential. A single reading can be misleading in either direction. Get a fasting baseline, then retest in three to six months if you are making dietary or exercise changes. After that, annual monitoring gives you a trajectory that is far more informative than any individual number. If you see a rising trend over two or three draws, that pattern tells you more than a single elevated result.

When Results Can Be Misleading

Several factors can distort a single proinsulin reading and lead you to the wrong conclusion.

  • Fasting status: Proinsulin rises substantially after eating. Reference values climb from about 2.7 to 14.2 pmol/L when fasting to 11.9 to 70.5 pmol/L two hours after a glucose load. A non-fasting draw will produce a meaninglessly elevated number.
  • Body weight: Fasting proinsulin increases significantly with BMI. In one study of prepubertal children, lean subjects averaged about 7.2 pmol/L while obese subjects averaged about 16.5 pmol/L, independent of insulin resistance. Your weight at the time of testing directly affects interpretation.
  • Corticosteroids and growth hormone: Short-term treatment with prednisone or growth hormone can more than double the proinsulin-to-insulin ratio within a week. If you are taking either, mention it when interpreting results.
  • Glucose tolerance status: If you already have impaired glucose tolerance or diabetes, your proinsulin and proinsulin-to-insulin ratio will be substantially higher than in someone with normal glucose metabolism, reflecting existing beta cell strain rather than a new finding.

Ethnic Differences in Interpretation

Your background can affect what your proinsulin number means. A study comparing African American and European American adults found that African Americans had higher fasting and post-glucose proinsulin-to-C-peptide ratios even after adjusting for insulin sensitivity. The relationship between proinsulin processing and beta cell function also differed by ethnicity: the proinsulin-to-C-peptide ratio predicted beta cell efficiency only in African Americans, not in European Americans. These differences mean that a single set of cutpoints may not apply equally across populations.

What Moves This Biomarker

Evidence-backed interventions that affect your Proinsulin level

Decrease
Start intensive insulin therapy (multiple daily injections or an insulin pump) in newly diagnosed type 2 diabetes
2 to 5 weeks of intensive insulin reduced the proinsulin-to-insulin ratio by about 8.7 to 10.8 percentage points, compared to only 4.1 points with oral medications. This effect persisted at one-year follow-up.
MedicationStrong Evidence
Increase
Take corticosteroids (prednisone) or growth hormone
Seven days of prednisone treatment more than doubled the proinsulin-to-insulin ratio (from about 14.7% to 33.9%). Growth hormone treatment raised it even further to about 40.9%.
MedicationStrong Evidence
Decrease
Follow a calorie-controlled diet (25 to 30 kcal/kg ideal body weight) designed for weight loss
In people with newly diagnosed type 2 diabetes, 16 weeks of dietary treatment reduced fasting intact proinsulin from about 31 pmol/L to about 13 pmol/L, roughly a 58% reduction.
DietModerate Evidence
Decrease
Lose at least 10% of body weight over 6 or more weeks
Weight loss of at least 10% reduced proinsulin levels relative to total insulin in people with established type 2 diabetes, improving the efficiency of proinsulin-to-insulin conversion.
DietModerate Evidence
Decrease
Perform high-intensity interval training (4 x 4-minute bouts at 85 to 95% peak heart rate, three times per week)
16 weeks of high-volume HIIT reduced fasting intact proinsulin by 32% in participants without type 2 diabetes. Lower-volume HIIT (1 x 4 minutes) actually increased proinsulin by 14 to 34%.
ExerciseModerate Evidence
Decrease
Combine structured exercise training with metformin (500 mg three times daily)
12 weeks of exercise plus metformin reduced fasting proinsulin from about 18.6 to about 13.9 pmol/L (approximately 25% reduction). Exercise alone did not significantly change proinsulin in this study.
ExerciseModerate Evidence
Increase
Take a sulfonylurea (such as glyburide/glibenclamide)
Sulfonylureas raised proinsulin levels relative to metformin over 6 months, and rosiglitazone reduced both proinsulin and the proinsulin-to-insulin ratio more effectively than glyburide.
MedicationModerate Evidence
Decrease
Take a thiazolidinedione (rosiglitazone or pioglitazone)
Rosiglitazone reduced circulating proinsulin and the proinsulin-to-insulin ratio compared to glyburide in people with type 2 diabetes. Pioglitazone also lowered proinsulin in non-diabetic patients at cardiovascular risk.
MedicationModerate Evidence
Decrease
Take metformin as a first-line diabetes medication
Over 6 months, metformin-treated patients had lower proinsulin levels compared to sulfonylurea-treated patients, though the overall group did not show a statistically significant proinsulin reduction.
MedicationModest Evidence
Decrease
Take anakinra (an interleukin-1 receptor blocker) at 100 mg daily by injection
13 weeks of anakinra reduced the proinsulin-to-insulin ratio compared to placebo in a randomized trial, alongside improved blood sugar control.
MedicationModest Evidence

Frequently Asked Questions

References

57 studies
  1. Liu M, Weiss MA, Arunagiri aDiabetes, Obesity & Metabolism2018
  2. Steiner DF, Park SY, Støy J, Philipson LH, Bell GIDiabetes, Obesity & Metabolism2009
  3. Liu M, Wright J, Guo H, Xiong Y, Arvan PVitamins and Hormones2014
  4. Jacobsen LM, Schatz DAJAMA2026
  5. Yang Y, Hua QX, Liu JThe Journal of Biological Chemistry2010